Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-aminolevulinic acid plus sodium ferrous citrate add-on therapy in adults with inadequately controlled type 2 diabetes mellitus
2017-004959-23Phase 2Completed
- Sponsor
- Neopharma Japan
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing 5-ALA/SFC plus background oral antidiabetic therapy with Placebo plus background oral antidiabetic therapy (2 arms). Primary endpoint: Mean change from baseline in glycated hemoglobin to Week 24. Started May 2018; status: completed.
02
Drugs
5-aminolevulinic acidsodium ferrous citrate
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-004959-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004959-23.